In This Issue
This China Newsletter provides an overview of key developments during Q2 2023 in the following areas:
Antitrust
- SAMR seeks Comments on Anti-Monopoly Compliance Guidelines for Concentrations of Undertakings
.
Compliance
- China to Strengthen Supervision over Online Cosmetics Operations
- China Releases Newly Amended Anti-Espionage Law
- MEE Publishes Measures for Ecological and Environmental Administrative Penalties
- SAMR to Regulate Advertising Censorship for Drugs, Medical Devices, Dietary Supplements and FSMPs
.
Data Privacy & Cybersecurity
- TC260 Issues Implementation Guidelines for Risk Assessment of Network Data Security
- CAC Publishes Guidelines for Filing of the SCCs
.
Health & Life Science
- NMPA to Tighten Regulation of MAHs for Entrusted Production of Drugs
- China Unveils Implementing Rules on the Administration of Human Genetic Resources
.
Private Equity Funds
- AMAC Solicits Comments on the Guidelines for the Operation of Private Securities Investment Funds
* This GT Newsletter is limited to non-U.S. matters and law.